2024 Rome, Italy

II-74 Erwin Dreesen
Anti-drug antibodies, low serum albumin and high C-reactive protein increase infliximab clearance in patients with inflammatory bowel disease: a population pharmacokinetic study of the TAXIT trial
Wednesday 15:10-16:30